MedTrace Logo

Osteopontin in Metastatic Breast Cancer Patients

NCT04274504 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2020-02-18

No results posted yet for this study

Summary

OPN plays an important role in various aspects of malignancy, particularly those involved in tissue invasion and metastasis, and OPN levels have been associated with aggressive¬ness in several cancer types, including breast cancer. Tumor response to treatment is a predictor of prognosis and overall survival for cancer patient population the investigators assigned osteopontin as potential contributors in breast cancer.

Conditions

  • Survival, Prosthesis

Interventions

DIAGNOSTIC_TEST

Osteopontin

Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Mohamed A Elbaiomy · Mansoura university Oncology Center

Eligibility

Min Age
31 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-10-31
Completion
2019-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274504 on ClinicalTrials.gov